and Darren R. Carpizo
SH Greco, K Spencer - Precision Molecular Pathology of Liver Cancer - Springer
… for the treatment of metastatic colon cancer in combination with … Additionally, a phase II trial
of erlotinib plus bevacizumab … A phase II study of gemcitabine and cisplatin in patients with …
of erlotinib plus bevacizumab … A phase II study of gemcitabine and cisplatin in patients with …
Impact of genetic targets on cancer therapy: hepatocellular cancer
… A phase 3 trial of erlotinib in combination with sorafenib … Currently, there are 4 mAbs against
IGF1R (cixutumumab, … targets and activates TRAIL receptor 1 (death receptor 4). Promising …
IGF1R (cixutumumab, … targets and activates TRAIL receptor 1 (death receptor 4). Promising …
Systems biology and molecular characterization of subtypes to guide targeted therapies in gastric cancer
MPG Dings, L Vermeulen, MF Bijlsma - Research and Clinical Applications …, 2021 - Elsevier
… extrinsic growth factors or insensitivity to anti-growth signals. … CRC and pancreatic ductal
adenocarcinoma (PDAC) (which … The insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1R) …
adenocarcinoma (PDAC) (which … The insulin-like growth factor 1 (IGF1)/IGF1 receptor (IGF1R) …
Potent molecular-targeted therapies for advanced esophageal squamous cell carcinoma
… (EGFR) and fibroblast growth factor receptor 1 (FGFR1) serve … in a phase II trial of second-line
paclitaxel plus cixutumumab in … In a phase III trial of erlotinib in combination with dCRT in …
paclitaxel plus cixutumumab in … In a phase III trial of erlotinib in combination with dCRT in …
From targets to targeted therapies in hepatocellular carcinoma
M Cervello, MR Emma, G Augello, D Balasus… - Onco …, 2014 - dl.begellhouse.com
… , gemcitabine and oxaliplatin, or other targeted agents, such as … , sorafenib in combination
with erlotinib was compared with … IMC-A12 (cixutumumab) is one of the best characterized …
with erlotinib was compared with … IMC-A12 (cixutumumab) is one of the best characterized …
[HTML][HTML] Establishment and characterization of 6 novel patient-derived primary pancreatic ductal adenocarcinoma cell lines from Korean pancreatic cancer patients
MJ Kim, MS Kim, SJ Kim, S An, J Park, H Park… - Cancer Cell …, 2017 - Springer
… More than 90% of pancreatic cancer patients show KRAS … /DPC4 and TP53 are mutated at
later stages [25, 46]. To … the interactions of TP53 and DPC4 signaling pathways. In total, 3 cell …
later stages [25, 46]. To … the interactions of TP53 and DPC4 signaling pathways. In total, 3 cell …
[引用][C] Systems biology and molecular characterization to guide targeted of therapies subtypes in gastric cancer
MPG Dingsa, L Vermeulena… - Research and Clinical …, 2021 - Academic Press
Molecular pathways of human adrenocortical carcinoma—translating cell signalling knowledge into diagnostic and treatment options
P Szyszka, AB Grossman, S Diaz-Cano… - Endokrynologia …, 2016 - journals.viamedica.pl
… recurrent/ metastatic ACC assessing the efficacy of cixutumumab … combined treatment with
erlotinib and gemcitabine as salvage … The combination of insulin-like growth factor receptor 1 (…
erlotinib and gemcitabine as salvage … The combination of insulin-like growth factor receptor 1 (…
Exploring the Mechanobiology of Pancreatic Cancer using Tumour Microenvironment Models
E Peerani - 2021 - qmro.qmul.ac.uk
… pancreatic cancer initiation, progression and metastasis, … -IGF1 antibodies ganitumab and
cixutumumab 40, have also … combinational erlotinib treatment over gemcitabine alone 41. …
cixutumumab 40, have also … combinational erlotinib treatment over gemcitabine alone 41. …